Search results

Order by most recent / most popular / relevance

Results: 1-10 of 3,110

U.S. Supreme Court holds that “reverse payment” patent litigation settlements are not immune from antitrust review

Osler, Hoskin & Harcourt LLP
-
Canada, USA
-
June 19 2013

In a significant ruling involving both intellectual property rights and competition policy, the Supreme Court of the United States held in a 5-3

Supreme Court revives FTC reverse payment challenge; says agreements can violate antitrust laws

Williams Mullen
-
USA
-
June 18 2013

The U.S. Supreme Court has issued one of its more anticipated rulings of this term in a decision that aims squarely at the intersection of antitrust

Update: are the regulators coming for the patent trolls?

Baker & Hostetler LLP
-
USA
-
June 18 2013

We recently wrote about a workshop held by the Department of Justice and the Federal Trade Commission to discuss perceived abuses by patent

Supreme Court rules that reverse payment settlement agreements are not presumptively unlawful but may be challenged under antitrust laws

Brinks Hofer Gilson & Lione
-
USA
-
June 18 2013

Supreme Court Rules that "Reverse Payment" Settlement Agreements are not Presumptively Unlawful but may be Challenged Under Antitrust Laws On June 17

Supreme Court holds that "reverse payment" patent settlements are subject to potential antitrust condemnation, but only after full-blown rule of reason review

Morrison & Foerster LLP
-
USA
-
June 18 2013

In FTC v. Actavis, Inc., 570 U.S. ____ (Slip Op. June 17, 2013), the Supreme Court addressed for the first time the underlying antitrust merits of the

U.S. Supreme Court rules that ‘reverse payments’ in Hatch-Waxman litigation settlement agreements must be scrutinized under antitrust laws

Greenberg Traurig LLP
-
USA
-
June 18 2013

On June 17, 2013, the Supreme Court of the United States issued a 53 decision in FTC v. Actavis.1 The Court reversed an 11th Circuit decision

Supreme Court overturns Eleventh Circuit in reverse payment case

Hogan Lovells
-
USA
-
June 18 2013

On Monday, 17 June the Supreme Court finally weighed in on the issue of pharmaceutical patent settlement agreements involving so-called "reverse

Supreme Court permits anti-trust scrutiny of “pay for delay” settlements

Bryan Cave LLP
-
USA
-
June 18 2013

The Court has held that so-called "reverse payment" or "pay for delay" settlement agreements used between brand name drug makers and their generic

The Supreme Court heightens antitrust scrutiny for ANDA reverse payment agreements between pharmaceutical companies

Sterne Kessler Goldstein & Fox
-
USA
-
June 18 2013

The U.S. Supreme Court yesterday ruled on the long-awaited FTC v. Actavis case concerning ANDA reverse payments, resolving a sharp circuit split. The

Supreme Court says ‘reverse payment’ generic drug settlements are subject to rule of reason antitrust review

Debevoise & Plimpton LLP
-
USA
-
June 18 2013

On June 17, 2013, the U.S. Supreme Court issued a much anticipated ruling in Federal Trade Commission v. Actavis, Inc. regarding the validity of

next >

Search results

U.S. Supreme Court holds that “reverse payment” patent litigation settlements are not immune from antitrust review

Supreme Court revives FTC reverse payment challenge; says agreements can violate antitrust laws

Update: are the regulators coming for the patent trolls?

Supreme Court rules that reverse payment settlement agreements are not presumptively unlawful but may be challenged under antitrust laws

Supreme Court holds that "reverse payment" patent settlements are subject to potential antitrust condemnation, but only after full-blown rule of reason review

U.S. Supreme Court rules that ‘reverse payments’ in Hatch-Waxman litigation settlement agreements must be scrutinized under antitrust laws

Supreme Court overturns Eleventh Circuit in reverse payment case

Supreme Court permits anti-trust scrutiny of “pay for delay” settlements

The Supreme Court heightens antitrust scrutiny for ANDA reverse payment agreements between pharmaceutical companies

Supreme Court says ‘reverse payment’ generic drug settlements are subject to rule of reason antitrust review

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea